吉西他滨+顺铂同步放化疗治疗局部晚期鼻咽癌患者的临床疗效及安全性  

Clinical efficacy and safety of gemcitabine+cisplatin concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma patients

作　　者：袁东杰[1] 李艳峰 李靖[1] 卢振民[1] 王慧敏[1] YUAN Dongjie;LI Yanfeng;LI Jing;LU Zhenmin;WANG Huimin(Ward I,Department of Otolaryngology,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China)

机构地区：[1]新乡医学院第一附属医院耳鼻咽喉科一病区,河南新乡453100

出　　处：《癌症进展》2025年第2期192-194,198,共4页Oncology Progress

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20200508)。

摘　　要：目的探讨吉西他滨+顺铂同步放化疗治疗局部晚期鼻咽癌患者的临床疗效及安全性。方法根据治疗方案的不同将96例局部晚期鼻咽癌患者分为对照组(n=47)和观察组(n=49),对照组患者接受紫杉醇+顺铂同步放化疗,观察组患者接受吉西他滨+顺铂同步放化疗。比较两组患者的临床疗效、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)]水平及不良反应发生情况。结果观察组患者的总有效率为85.71%,明显高于对照组患者的55.32%,差异有统计学意义(P﹤0.01)。治疗后,两组患者血清SCCAg、CYFRA21-1水平均低于本组治疗前,观察组患者血清SCC-Ag、CYFRA21-1水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者恶心呕吐、白细胞减少、肝功能减退及贫血发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论吉西他滨+顺铂同步放化疗治疗局部晚期鼻咽癌的效果显著,可降低肿瘤标志物水平,且不良反应发生率低。Objective To investigate the clinical efficacy and safety of gemcitabine+cisplatin concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma patients.Method A total of 96 patients with locally advanced nasopharyngeal carcinoma were divided into control group(n=47)and observation group(n=49)according to different treatment methods.Patients in the control group received paclitaxel+cisplatin concurrent chemoradiotherapy,while patients in the observation group received gemcitabine+cisplatin concurrent chemoradiotherapy.The clinical efficacy,tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCCAg)]levels,and incidence of adverse reactions were compared between the two groups.Result The total effective rate in observation group was 85.71%,significantly higher than 55.32%in control group,and the difference was statistically significant(P<0.01).After treatment,the levels of SCC-Ag and CYFRA21-1 in both groups were lower than those before treatment,the levels of SCC-Ag and CYFRA21-1 in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).The incidences of nausea,vomiting,leukopenia,liver dysfunction,and anemia in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).Conclusion The gemcitabine+cisplatin concurrent chemoradiotherapy has significant effects on the treatment of locally advanced nasopharyngeal carcinoma,which can reduce tumor marker levels and has a low incidence of adverse reactions.

关 键 词：鼻咽癌 顺铂 吉西他滨 紫杉醇 疗效 安全性 

分 类 号：R739.6[医药卫生—肿瘤]